Supreme Bio Tech Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
as on 16-11-2024
- Paid Up Capital ₹ 1.20 M
as on 16-11-2024
- Company Age 32 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 0.80 M
as on 16-11-2024
- Revenue -5.30%
(FY 2023)
- Profit 49.59%
(FY 2023)
- Ebitda 59.23%
(FY 2023)
- Net Worth -33.77%
(FY 2023)
- Total Assets -3.23%
(FY 2023)
About Supreme Bio Tech
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 1.20 M.
The company currently has active open charges totaling ₹0.80 M.
Sham Singla, Parvinder Gulati, Lagan Singh, and One other member serve as directors at the Company.
- CIN/LLPIN
U51397CH1992PTC012509
- Company No.
012509
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Jul 1992
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Chandigarh, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Supreme Bio Tech?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sham Singla  | Director | 13-Dec-2020 | Current |
| Parvinder Gulati | Director | 30-Jul-1992 | Current |
| Lagan Singh | Director | 22-Dec-2011 | Current |
| Gurmeet Narula | Director | 30-Jul-1992 | Current |
Financial Performance and Corporate Structure Insights of Supreme Bio Tech.
Supreme Bio Tech Pvt Ltd, for the financial year ended 2023, experienced Minor drop in revenue, with a 5.3% decrease. The company also saw a substantial improvement in profitability, with a 49.59% increase in profit. The company's net worth observed a substantial decline by a decrease of 33.77%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Supreme Bio Tech?
In 2023, Supreme Bio Tech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Mdc Pharmaceuticals LimitedActive 30 years 5 monthsSham Singla, Parvinder Gulati and 1 more are mutual person
Lifestyle Bio Sciences Private LimitedActive 15 years 13 daysSham Singla, Parvinder Gulati and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of India Creation Date: 01 May 2000 | ₹0.60 M | Open |
Punjab National Bank Creation Date: 13 Oct 1992 | ₹0.20 M | Open |
How Many Employees Work at Supreme Bio Tech?
Unlock and access historical data on people associated with Supreme Bio Tech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Supreme Bio Tech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Supreme Bio Tech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
